BsAbs targeting myeloma cell antigens beyond BCMA have demonstrated potential in heavily pretreated R/R MM patients, including those who have previously received BCMA-targeted treatments [99]. The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.